Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Staar Surgical TICL

This article was originally published in The Gray Sheet

Executive Summary

Toric implantable contact lens gains conditional investigational device exemption clearance for a 125-patient U.S. trial to treat myopia of -3.0 to -20 diopters and astigmatism of 1.0 to 4.0 diopters. The device "is the only phakic intraocular lens" for pre-existing astigmatism and myopia, Staar says. An ongoing U.S. study of a non-toric myopia version, including 529 enrolled cases, shows a 2.3% incidence of lens opacities, with eight of the 12 opacities being "non progressive and showing no loss of best-corrected visual acuity," Staar notes...

You may also be interested in...



Staar Surgical TICL

Receipt of CE mark for toric implantable contact lens EU sales makes Staar's TICL the first posterior phakic intraocular lens able to reduce pre-existing astigmatism alongside myopia or hyperopia correction, the company says Dec. 3. The Monrovia, Calif. firm gained conditional IDE clearance in January for a 125-patient U.S. trial investigating the TICL to treat myopia of -3.0 to 20 diopters - and astigmatism of 1.0 to 4.0 D (1"The Gray Sheet" Jan. 14, 2002, In Brief). Staar implanted the first device in a U.S. patient's eye in August, with "excellent results [and] no surprises"...

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

Polpharma Pursues Tysabri Through Antelope Trial

The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.

UsernamePublicRestriction

Register

MT015954

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel